Trinity Biotech PLC represents a strong commitment to innovation, quality, and patient care in the field of biotechnology. With a focus on diagnostic products and immunoassay technology, Trinity Biotech is dedicated to improving healthcare outcomes and facilitating accurate disease detection. The company's corporate philosophy centers around providing reliable and cost-effective solutions, addressing unmet medical needs, and ensuring customer satisfaction. Trinity Biotech PLC strives to maintain high ethical standards, foster a culture of teamwork and collaboration, and cultivate long-term relationships with healthcare professionals and stakeholders. Through their dedication to excellence, Trinity Biotech PLC is positioned as a trusted leader in the biotech industry.

Trinity Biotech PLC is primarily present in numerous countries and regions globally. With its strong global presence, Trinity Biotech has established a solid footing in markets across North America, Europe, Asia-Pacific, and Latin America. The company has successfully expanded its reach to countries including the United States, United Kingdom, Germany, France, Italy, China, India, Japan, Brazil, and Argentina, among others. Trinity Biotech PLC's widespread presence allows it to effectively cater to a diverse customer base and deliver its innovative healthcare solutions on a larger scale.

Trinity Biotech PLC has achieved several significant milestones throughout its history. These include developing and commercializing advanced diagnostic solutions for infectious diseases, autoimmune disorders, and diabetes. The company has expanded its global presence by establishing a strong presence in various countries. Trinity Biotech has also gained recognition for its commitment to research and development, leading to the introduction of novel and innovative products. Moreover, the company has built strong partnerships with leading healthcare institutions and organizations worldwide, fostering collaboration and knowledge-sharing to enhance patient care. Trinity Biotech PLC continues to strive for excellence in delivering reliable and accurate diagnostic solutions, positioning itself as a trusted leader in the medical diagnostics field.

Trinity Biotech PLC is a leading company in the field of diagnostics and clinical chemistry. Established in 1992, Trinity Biotech has a rich history of delivering innovative medical solutions globally. With a focus on developing and marketing diagnostic products, the company has built a strong reputation for its high-quality healthcare solutions. Trinity Biotech's expertise lies in areas such as infectious diseases, autoimmune disorders, and diabetes, offering a wide range of diagnostic products for accurate and reliable testing. Committed to advancing patient care, Trinity Biotech continues to drive advancements in the field of clinical diagnostics and deliver improved healthcare outcomes worldwide.

The main competitors of Trinity Biotech PLC in the market include companies such as Abbott Laboratories, Bio-Rad Laboratories Inc., Siemens Healthineers, and Thermo Fisher Scientific Inc. These companies operate in the same industry and offer similar products and services. Trinity Biotech PLC faces competition from these established players, who also strive to provide innovative solutions and maintain a strong market presence. However, Trinity Biotech PLC has managed to differentiate itself through its unique product offerings and continued focus on research and development, ensuring its position as a prominent player in the market.

Trinity Biotech PLC is primarily active in the healthcare and medical diagnostics industries. As a leading global provider of diagnostic solutions, Trinity Biotech specializes in the development, manufacture, and marketing of diagnostic products for clinical laboratory and point-of-care testing. With a focus on infectious diseases, autoimmune disorders, and diabetes management, Trinity Biotech offers a range of innovative and accurate diagnostic tests. Their commitment to improving patient outcomes and delivering high-quality diagnostic solutions has made them a trusted name in the healthcare industry.

The business model of Trinity Biotech PLC is focused on developing, manufacturing, and marketing diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. Trinity Biotech specializes in the field of in vitro diagnostics with a particular emphasis on infectious diseases and autoimmune disorders. The company operates through two primary segments: clinical laboratory diagnostic products and POC products. Trinity Biotech aims to provide accurate and reliable diagnostic solutions to healthcare professionals and patients worldwide. With its diverse portfolio of innovative products and a focus on improving patient outcomes, Trinity Biotech PLC continues to be a leading player in the diagnostic industry.

De Trinity Biotech K/W is -3,33.

De Trinity Biotech KUV is 4,05.

De AlleAktien Kwaliteitsscore voor Trinity Biotech is 3/10.

De verwachte Trinity Biotech omzet is 66,86 mln. USD.

De verwachte Trinity Biotech winst is -81,48 mln. USD.

Trinity Biotech PLC is a global company specializing in the development, manufacturing, and marketing of diagnostic test kits. Its business model focuses on providing high-quality test kits for various health areas, including infectious diseases, diabetes, hematology, cardiovascular diseases, and oncology. The company's diagnostic division offers a wide range of test kits aimed at multiple markets, with a particular focus on tests for diagnosing HIV/AIDS and other infectious diseases. They also offer tests for determining tumor markers, hemoglobin levels, and uric acid levels. Trinity Biotech PLC also has divisions specializing in clinical chemistry, hematology, and immunology, offering test kits for diagnosing and monitoring various conditions in those fields. The company also provides services to support the implementation of test kits, including consultation, staff training, quality assurance control, and ongoing customer support. One of the company's innovative developments is the Premier Hb9210 hemoglobin test based on HPLC technology, which allows users to perform hemoglobin tests independent of common alcohol- and smoke-induced interferences. This test is currently the only clinically significant method for quantitatively determining hemoglobin variants and laboratory instrument stability. Overall, Trinity Biotech PLC aims to provide high-quality test kits while focusing on customer needs, and as a result, it has established itself as a trusted provider of diagnostic test kits.

Trinity Biotech keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Trinity Biotech of het bedrijf keert geen dividend uit.

De ISIN van Trinity Biotech is US8964383066.

Het WKN van Trinity Biotech is A0ET3S.

De ticker van Trinity Biotech is TRIB.

Binnen de laatste 12 maanden betaalde Trinity Biotech een dividend van 0,22 USD . Dit komt overeen met een dividendrendement van ongeveer 12,43 %. Voor de komende 12 maanden zal Trinity Biotech naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Trinity Biotech is momenteel 12,43 %.

Trinity Biotech betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden juli, juli, juli, juli.

Trinity Biotech betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Trinity Biotech wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Trinity Biotech van 1-7-2015 ter hoogte van 0,22 USD te ontvangen, moest je het aandeel voor de ex-datum op 5-6-2015 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 1-7-2015.

In het jaar 2023 heeft Trinity Biotech 0 USD aan dividenden uitgekeerd.

De dividenden van Trinity Biotech worden in USD uitgekeerd.